1. Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update. Support Care Cancer. 2005;13(2):80-4. http://doi.org/10.1007/s00520-004-0718-y
2. Ishikawa A, Ohara G, Nakazawa K, Tamura T, Sato S, Kagohashi K, et al. Chemotherapy-induced complications in patients with lung cancer: An evaluation by pharmacists. Mol Clin Oncol. 2013;1(1):65-8. http://doi.org/10.3892/mco.2012.33
3. Mitchell EP. Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol. 2006;33(1):106-20. http://doi.org/10.1053/j.seminoncol.2005.12.001
4. Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016;374(14):1356-67. http://doi.org/10.1056/NEJMra1515442
5. Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119-v33. http://doi.org/10.1093/annonc/mdw270
6. Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, et al. NCCN Guidelines Insights: Antiemesis, Version 2.2017. J Natl Compr Canc Netw. 2017;15(7):883-93. http://doi.org/10.6004/jnccn.2017.0117
7. Baba Y, Baba H, Yamamoto S, Shimada H, Shibata T, Miyazaki T, et al. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan. Dis Esophagus. 2017;30(2):1-7. http://doi.org/10.1111/dote.12482
8. Xiao Y, Liu YY, Yu KQ, Ouyang MZ, Luo R, Zhao XS. Chinese herbal medicine liu jun zi tang and xiang sha liu jun zi tang for functional dyspepsia: meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2012;2012:936459. http://doi.org/10.1155/2012/936459
9. Mogami S, Hattori T. Beneficial effects of rikkunshito, a Japanese kampo medicine, on gastrointestinal dysfunction and anorexia in combination with Western drug: a systematic review. Evid Based Complement Alternat Med. 2014;2014:519035. http://doi.org/10.1155/2014/519035
10. Tominaga K, Iwakiri R, Fujimoto K, Fujiwara Y, Tanaka M, Shimoyama Y, et al. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan. J Gastroenterol. 2012;47(3):284-92. http://doi.org/10.1007/s00535-011-0488-5
11. Shuji Takiguchi YH, Tsuyoshi Takahashi, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Hiroshi Miyata, Masaki Mori, Hiroshi Hosoda, Kenji Kangawa, Yuichiro Doki. Effect of rikkunshito, a Japanese herbal medicine, on gastrointestinal symptoms and ghrelin levels in gastric cancer patients after gastrectomy. Gastric Cancer. 2013;16:167-74. http://doi.org/10.1007/s10120-012-0164-3
12. Ko MH, Song SY, Ha SJ, Lee JY, Yoon SW, Park JH, et al. Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related Anorexia: A Randomized, Controlled Trial, Pilot Study. Integr Cancer Ther. 2021;20:15347354211019107. http://doi.org/10.1177/15347354211019107
13. Matsumura T, Arai M, Yonemitsu Y, Maruoka D, Tanaka T, Suzuki T, et al. The traditional Japanese medicine Rikkunshito increases the plasma level of ghrelin in humans and mice. J Gastroenterol. 2010;45(3):300-7. http://doi.org/10.1007/s00535-009-0166-z
14. Seike J, Sawada T, Kawakita N, Yamamoto Y, Yuasa Y, Yamai H, et al. A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP. Int J Surg Oncol. 2011;2011:715623. http://doi.org/10.1155/2011/715623
15. Ohnishi S, Watari H, Kanno M, Ohba Y, Takeuchi S, Miyaji T, et al. Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02). J Gynecol Oncol. 2017;28(5):e44. http://doi.org/10.3802/jgo.2017.28.e44
16. Harada T, Amano T, Ikari T, Takamura K, Ogi T, Fujikane T, et al. Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials. Front Pharmacol. 2017;8:972. http://doi.org/10.3389/fphar.2017.00972
17. Hirose C, Iihara H, Funaguchi N, Endo J, Ito F, Yanase K, et al. Prophylactic effect of rikkunshito, an herbal medicine, for chemotherapy-induced nausea in thoracic cancer patients receiving carboplatin-based chemotherapy. Die Pharmazie. 2019;74(10):620-4. http://doi.org/10.1691/ph.2019.9497
18. Hamai Y, Yoshiya T, Hihara J, Emi M, Furukawa T, Yamakita I, et al. Traditional Japanese herbal medicine rikkunshito increases food intake and plasma acylated ghrelin levels in patients with esophageal cancer treated by cisplatin-based chemotherapy. J Thorac Dis. 2019;11(6):2470-8. http://doi.org/10.21037/jtd.2019.05.67
19. Yoshiya T, Mimae T, Ito M, Sasada S, Tsutani Y, Satoh K, et al. Prospective, randomized, cross-over pilot study of the effects of Rikkunshito, a Japanese traditional herbal medicine, on anorexia and plasma-acylated ghrelin levels in lung cancer patients undergoing cisplatin-based chemotherapy. Invest New Drugs. 2020;38(2):485-92. http://doi.org/10.1007/s10637-019-00836-x
20. Takeda H, Sadakane C, Hattori T, Katsurada T, Ohkawara T, Nagai K, et al. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology. 2008;134(7):2004-13. http://doi.org/10.1053/j.gastro.2008.02.078
21. Yakabi K, Kurosawa S, Tamai M, Yuzurihara M, Nahata M, Ohno S, et al. Rikkunshito and 5-HT2C receptor antagonist improve cisplatin-induced anorexia via hypothalamic ghrelin interaction. Regul Pept. 2010;161(1-3):97-105. http://doi.org/10.1016/j.regpep.2010.02.003
22. M Kojima HH, Y Date, M Nakazato, H Matsuo, K Kangawa. Ghrelin is a growth-hormonereleasing acylated peptide from stomach. Nature. 1999;402:656-60. http://doi.org/10.1038/45230.
23. Fujitsuka N, Uezono Y. Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome. Front Pharmacol. 2014;5:271. http://doi.org/10.3389/fphar.2014.00271
24. Hoshino N, Nishizaki D, Hida K, Obama K, Sakai Y. Rikkunshito for upper gastrointestinal symptoms: A systematic review and meta-analysis. Complement Ther Med. 2019;42:255-63. http://doi.org/10.1016/j.ctim.2018.11.025
25. Van Lancker A, Velghe A, Van Hecke A, Verbrugghe M, Van Den Noortgate N, Grypdonck M, et al. Prevalence of symptoms in older cancer patients receiving palliative care: a systematic review and meta-analysis. J Pain Symptom Manage. 2014;47(1):90-104. http://doi.org/10.1016/j.jpainsymman.2013.02.016
26. Aurélie, Van, Lancke, Dimitri, Beeckma, Nele, et al. Frequency and intensity of symptoms and treatment interventions in hospitalized older palliative cancer patients: a multicentre cross-sectional study. Journal of Advanced Nursing. 2016. http://doi.org/ 10.1111/jan.13230
27. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015;4:1. http://doi.org/10.1186/2046-4053-4-1
28. Furlan AD, Malmivaara A, Chou R, Maher CG, Deyo RA, Schoene M, et al. 2015 Updated Method Guideline for Systematic Reviews in the Cochrane Back and Neck Group. Spine (Phila Pa 1976). 2015;40(21):1660-73. http://doi.org/10.1097/BRS.0000000000001061
29. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC medical research methodology. 2014;14:135. http://doi.org/10.1186/1471-2288-14-135
30. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol. 2011;64(12):1311-6. http://doi.org/10.1016/j.jclinepi.2011.06.004
31. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-101.
32. Song F, Gilbody S. Bias in meta-analysis detected by a simple, graphical test. Increase in studies of publication bias coincided with increasing use of meta-analysis. BMJ (Clinical research ed). 1998;316(7129):471.
33. Inokuchi K, Masaoka T, Kanai T. Rikkunshito as a Therapeautic Agent for Functional Dyspepsia and its Prokinetic and Non-Prokinetic Effects. Front Pharmacol. 2021;12:640576. http://doi.org/10.3389/fphar.2021.640576
34. Hoshino N, Nishizaki D, Hida K, Obama K, Sakai Y. Rikkunshito for upper gastrointestinal symptoms: A systematic review and meta-analysis. Complementary Therapies in Medicine. 2019;42:255-63. http://doi.org/10.1016/j.ctim.2018.11.025